Efficacy of Tucidinostat Pre-emptive Therapy for Peripheral T-cell Lymphoma after Allogeneic Stem Cell Transplantation.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: refractory PTCL who underwent allo-SCT followed by preemptive therapy with tucidinostat
I · Intervention 중재 / 시술
allo-SCT followed by preemptive therapy with tucidinostat
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The patient has maintained complete remission for 2-years. Thus, given its mechanism, tucidinostat may be a viable option for post-transplant therapy.
Recently, various molecular targeted therapies have been developed for peripheral T-cell lymphoma (PTCL).
APA
Takada K, Tachi N, et al. (2026). Efficacy of Tucidinostat Pre-emptive Therapy for Peripheral T-cell Lymphoma after Allogeneic Stem Cell Transplantation.. Internal medicine (Tokyo, Japan), 65(2), 318-321. https://doi.org/10.2169/internalmedicine.5535-25
MLA
Takada K, et al.. "Efficacy of Tucidinostat Pre-emptive Therapy for Peripheral T-cell Lymphoma after Allogeneic Stem Cell Transplantation.." Internal medicine (Tokyo, Japan), vol. 65, no. 2, 2026, pp. 318-321.
PMID
40571612 ↗
Abstract 한글 요약
Recently, various molecular targeted therapies have been developed for peripheral T-cell lymphoma (PTCL). However, relapsed/refractory (r/r) PTCL is associated with poor outcomes. Allogeneic stem cell transplantation (allo-SCT) can be effective against r/r PTCL owing to its graft-versus-lymphoma effect. Nevertheless, a posttransplant relapse is common. Although post-transplant preemptive therapy has shown favorable outcomes in leukemia, reports on its use for PTCL are extremely limited. We herein present the case of a patient with refractory PTCL who underwent allo-SCT followed by preemptive therapy with tucidinostat. The patient has maintained complete remission for 2-years. Thus, given its mechanism, tucidinostat may be a viable option for post-transplant therapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (3)
- Endometrial microbiota in maternal-fetal tolerance: An in vitro study of extravillous trophoblasts and uNK cells.
- Assessment of the Role of Neutrophil-Lymphocyte Ratio as a Prognostic Biomarker in Breast Cancer Patients: A Cross-sectional Study.
- Clinicopathological Significance of HER2 Expression Redefined by the HER2-low Concept in Ductal Carcinoma .
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.